| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Cinnamtannin B1 targets multiple cellular pathways involved in oxidative stress, inflammation, and cell signaling. It has been shown to activate the AMPK pathway, which is involved in energy metabolism and insulin sensitivity. Cinnamtannin B1 also inhibits the NF-κB pathway, reducing inflammation. The compound's antioxidant activity is mediated through its ability to scavenge free radicals and to activate the Nrf2 pathway.
|
|---|---|
| ln Vitro |
In vitro, Cinnamtannin B1 has been shown to have potent antioxidant activity, as demonstrated by its ability to scavenge free radicals and to protect cells from oxidative stress. It also has anti-inflammatory activity, inhibiting the production of pro-inflammatory cytokines. Cinnamtannin B1 has been shown to inhibit the proliferation of various cancer cell lines. The compound also improves insulin sensitivity in adipocytes.
|
| ln Vivo |
In vivo, Cinnamtannin B1 has been studied in animal models of diabetes, obesity, and cancer. The compound has been shown to improve glucose tolerance and insulin sensitivity in diabetic mice. Cinnamtannin B1 also reduces inflammation and oxidative stress in animal models. The compound's anticancer activity has been demonstrated in xenograft mouse models.
|
| Enzyme Assay |
In vitro antioxidant assays for Cinnamtannin B1 typically involve measuring its ability to scavenge free radicals, such as DPPH, ABTS, or superoxide radicals. The compound is dissolved in an appropriate solvent and mixed with the radical solution. The decrease in absorbance is measured, and the IC50 value for radical scavenging is determined. The compound's reducing power and metal chelating activity can also be assessed.
|
| Cell Assay |
In vitro cell-based studies with Cinnamtannin B1 typically involve cultured cells, such as adipocytes, hepatocytes, or cancer cells. Cells are treated with Cinnamtannin B1 at various concentrations. The effect of the compound on glucose uptake, insulin signaling, and lipid metabolism is assessed. The compound's anti-inflammatory and antioxidant effects are evaluated by measuring cytokine production and oxidative stress markers. The effect of Cinnamtannin B1 on cell proliferation and apoptosis is also assessed.
|
| Animal Protocol |
In vivo animal studies with Cinnamtannin B1 are typically conducted in rodent models of diabetes, obesity, or cancer. The compound is administered orally or intraperitoneally. The effect of Cinnamtannin B1 on blood glucose, insulin sensitivity, and body weight is assessed. The compound's effect on tumor growth in xenograft models is evaluated. Pharmacokinetic studies are performed by measuring compound concentrations in plasma and tissues.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Cinnamtannin B1 have been studied in preclinical settings. Following oral administration, the compound is absorbed from the gastrointestinal tract. Cinnamtannin B1 is extensively metabolized in the liver and by gut microbiota. The bioavailability of Cinnamtannin B1 is relatively low, which is typical of proanthocyanidins. Detailed PK parameters have been reported in the literature.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Cinnamtannin B1 has been evaluated in preclinical studies. The compound has been shown to have a relatively low toxicity in animal models at therapeutic doses. However, high doses can cause adverse effects, including gastrointestinal upset. Cinnamtannin B1 is generally considered safe for consumption as part of a diet rich in polyphenols.
|
| References | |
| Additional Infomation |
Cinnamomum tannin B-1 is a proanthocyanidin found in cinnamon (Cinnamomum cassia) and Ceylon cinnamon (Cinnamomum zeylanicum). It is a cyclooxygenase 2 inhibitor and a plant metabolite. Cinnamomum tannin B-1 has also been reported in European cinnamon (Cinnamomum sieboldii), Philippine cinnamon (Cinnamomum philippinense), and other organisms with relevant data. See also: Cinnamon (partial).
Cinnamtannin B1 is a natural proanthocyanidin found in cinnamon and other plants. It has been studied for its potential health benefits, including antioxidant, anti-inflammatory, antidiabetic, and anticancer properties. Cinnamtannin B1 is a research compound used to study the biological activities of dietary polyphenols. The compound is not an FDA-approved drug and is not commercially available as a pharmaceutical product. |
| Molecular Formula |
C45H36O18
|
|---|---|
| Molecular Weight |
864.757
|
| Exact Mass |
864.19
|
| CAS # |
88082-60-4
|
| PubChem CID |
475277
|
| Appearance |
White to pink solid powder
|
| LogP |
4.242
|
| Hydrogen Bond Donor Count |
14
|
| Hydrogen Bond Acceptor Count |
18
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
63
|
| Complexity |
1610
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
C1[C@H]([C@H](OC2=C1C(=CC(=C2[C@@H]3[C@H]([C@H](OC4=C3C(=CC5=C4[C@@H]6[C@H]([C@](O5)(OC7=CC(=CC(=C67)O)O)C8=CC(=C(C=C8)O)O)O)O)C9=CC(=C(C=C9)O)O)O)O)O)C1=CC(=C(C=C1)O)O)O
|
| InChi Key |
BYSRPHRKESMCPO-LQNPQWRQSA-N
|
| InChi Code |
InChI=1S/C45H36O18/c46-18-10-27(54)33-31(11-18)62-45(17-3-6-22(49)26(53)9-17)44(59)38(33)36-32(63-45)14-29(56)35-37(39(58)41(61-43(35)36)16-2-5-21(48)25(52)8-16)34-28(55)13-23(50)19-12-30(57)40(60-42(19)34)15-1-4-20(47)24(51)7-15/h1-11,13-14,30,37-41,44,46-59H,12H2/t30-,37+,38-,39-,40-,41-,44-,45+/m1/s1
|
| Chemical Name |
(1R,5R,6R,7S,13S,21R)-5,13-bis(3,4-dihydroxyphenyl)-7-[(2R,3R)-2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-3,4-dihydro-2H-chromen-8-yl]-4,12,14-trioxapentacyclo[11.7.1.02,11.03,8.015,20]henicosa-2(11),3(8),9,15,17,19-hexaene-6,9,17,19,21-pentol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~115.64 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1564 mL | 5.7820 mL | 11.5639 mL | |
| 5 mM | 0.2313 mL | 1.1564 mL | 2.3128 mL | |
| 10 mM | 0.1156 mL | 0.5782 mL | 1.1564 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
